Rubicon Research Limited — JV/Acquisition, 15-04-2026: Acquisition

Rubicon Research is acquiring an 85% stake in Arinna Lifesciences, a pharma marketing firm focused on CNS products. This strategic move, valued at an enterprise level of ₹200 Cr (cash-free, debt-free), aims to leverage Rubicon's IP and chronic product portfolio. Arinna's sales and distribution network will bolster Rubicon's access to Indian patients and prescribers, particularly for its specialty products and drug-device combinations. This acquisition is expected to significantly expand Rubicon's domestic market reach within a core therapeutic segment.